The randomized, placebo-controlled dose titration trial, planned to enroll up to 30 healthy adult volunteers, is designed to evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD811 and the optimal titration schedule.
APD811 is a novel oral drug candidate that targets the prostacyclin (IP) receptor for the treatment of PAH.
Arena senior vice president and chief medical officer William Shanahan said, "APD811 has the potential to improve treatment for this life-threatening disorder by providing patients with an oral, once-daily option targeting the prostacyclin receptor."
PAH is a progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs.